Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174668
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nadal, Ernest | - |
dc.contributor.author | Bosch Barrera, Joaquim | - |
dc.contributor.author | Cedrés, S. | - |
dc.contributor.author | Coves, J. | - |
dc.contributor.author | García Campelo, R. | - |
dc.contributor.author | Guirado, M. | - |
dc.contributor.author | López Castro, Rafael | - |
dc.contributor.author | Ortega, A. L. | - |
dc.contributor.author | Vicente, D. | - |
dc.contributor.author | Castro Carpeño, Javier de | - |
dc.date.accessioned | 2021-03-05T07:21:18Z | - |
dc.date.available | 2021-03-05T07:21:18Z | - |
dc.date.issued | 2021-02-04 | - |
dc.identifier.uri | http://hdl.handle.net/2445/174668 | - |
dc.description.abstract | Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Springer Science and Business Media LLC | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1007/s12094-020-02532-2 | - |
dc.relation.ispartof | Clinical and Translational Oncology, 2021, Vol. 23, num.5, p. 980-987 | - |
dc.relation.uri | https://doi.org/10.1007/s12094-020-02532-2 | - |
dc.rights | cc by (c) Nadal, Ernest et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Mesotelioma | - |
dc.subject.classification | Protocols clínics | - |
dc.subject.classification | Diagnòstic | - |
dc.subject.other | Mesothelioma | - |
dc.subject.other | Medical protocols | - |
dc.subject.other | Diagnosis | - |
dc.title | SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020) | - |
dc.type | info:eu-repo/semantics/article | - |
dc.date.updated | 2021-03-04T08:58:27Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33538989 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Nadal2021_Article_SEOMClinicalGuidelinesForTheTr.pdf | 582.56 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License